Author
Listed:
- Nuria Diaz
(Lilly Research Laboratories)
- Carlos Perez
(Lilly Research Laboratories)
- Ana Maria Escribano
(Lilly Research Laboratories)
- Gema Sanz
(Lilly Research Laboratories)
- Julian Priego
(Lilly Research Laboratories)
- Celia Lafuente
(Lilly Research Laboratories)
- Mario Barberis
(Lilly Research Laboratories)
- Luis Calle
(Lilly Research Laboratories)
- Juan Felix Espinosa
(Lilly Research Laboratories)
- Birgit T. Priest
(Lilly Research Laboratories)
- Hong Y. Zhang
(Lilly Research Laboratories)
- Amanda K. Nosie
(Lilly Research Laboratories)
- Joseph V. Haas
(Lilly Research Laboratories)
- Ellen Cannady
(Lilly Research Laboratories)
- Anthony Borel
(Lilly Research Laboratories)
- Albert E. Schultze
(Lilly Research Laboratories)
- J. Michael Sauder
(Lilly Research Laboratories)
- Jörg Hendle
(Lilly Research Laboratories)
- Ken Weichert
(Lilly Research Laboratories)
- Stephen J. Nicholls
(Monash University)
- Laura F. Michael
(Lilly Research Laboratories)
Abstract
Lipoprotein(a) (Lp(a)), an independent, causal cardiovascular risk factor, is a lipoprotein particle that is formed by the interaction of a low-density lipoprotein (LDL) particle and apolipoprotein(a) (apo(a))1,2. Apo(a) first binds to lysine residues of apolipoprotein B-100 (apoB-100) on LDL through the Kringle IV (KIV) 7 and 8 domains, before a disulfide bond forms between apo(a) and apoB-100 to create Lp(a) (refs. 3–7). Here we show that the first step of Lp(a) formation can be inhibited through small-molecule interactions with apo(a) KIV7–8. We identify compounds that bind to apo(a) KIV7–8, and, through chemical optimization and further application of multivalency, we create compounds with subnanomolar potency that inhibit the formation of Lp(a). Oral doses of prototype compounds and a potent, multivalent disruptor, LY3473329 (muvalaplin), reduced the levels of Lp(a) in transgenic mice and in cynomolgus monkeys. Although multivalent molecules bind to the Kringle domains of rat plasminogen and reduce plasmin activity, species-selective differences in plasminogen sequences suggest that inhibitor molecules will reduce the levels of Lp(a), but not those of plasminogen, in humans. These data support the clinical development of LY3473329—which is already in phase 2 studies—as a potent and specific orally administered agent for reducing the levels of Lp(a).
Suggested Citation
Nuria Diaz & Carlos Perez & Ana Maria Escribano & Gema Sanz & Julian Priego & Celia Lafuente & Mario Barberis & Luis Calle & Juan Felix Espinosa & Birgit T. Priest & Hong Y. Zhang & Amanda K. Nosie & , 2024.
"Discovery of potent small-molecule inhibitors of lipoprotein(a) formation,"
Nature, Nature, vol. 629(8013), pages 945-950, May.
Handle:
RePEc:nat:nature:v:629:y:2024:i:8013:d:10.1038_s41586-024-07387-z
DOI: 10.1038/s41586-024-07387-z
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:629:y:2024:i:8013:d:10.1038_s41586-024-07387-z. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.